Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
Zymeworks Inc. (Nasdaq: ZYME) has appointed Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. With over 20 years of public company biotech experience, Patterson brings expertise in guiding strategy, finance, operations, and governance through various growth phases. She will be instrumental in supporting Zymeworks' '5 by 5' goal of having five novel antibody-drug conjugates or T cell engagers in clinical studies by 2026, and advancing R&D programs into clinical studies by 2027.
Patterson's prior roles include Chief Financial and Business Officer at Tenaya Therapeutics and leadership positions at Adverum Biotechnologies. She currently serves on the boards of Nkarta, Inc. and Oxford Biomedica. Based in Zymeworks' new Redwood City, California location, Patterson will focus on developing long-term financial strategies and supporting strategic business decisions.
Zymeworks Inc. (Nasdaq: ZYME) ha nominato Leone Patterson come Vicepresidente Esecutivo e Direttore Business e Finanziario, con effetto dal 1° settembre 2024. Con oltre 20 anni di esperienza nel settore biotech di aziende quotate in borsa, Patterson porta competenze nella definizione di strategie, finanza, operazioni e governance attraverso varie fasi di crescita. Sarà fondamentale nel supportare l'obiettivo di Zymeworks denominato '5 by 5', che prevede di avere cinque nuovi coniugati farmaco-anticorpo o attivatori di cellule T in studi clinici entro il 2026, e nell'avanzare i programmi di R&S verso studi clinici entro il 2027.
I ruoli precedenti di Patterson includono quello di Direttore Finanziario e Business Officer presso Tenaya Therapeutics e posizioni dirigenziali presso Adverum Biotechnologies. Attualmente ricopre anche cariche nel consiglio di amministrazione di Nkarta, Inc. e Oxford Biomedica. Con sede nella nuova location di Zymeworks a Redwood City, California, Patterson si concentrerà sullo sviluppo di strategie finanziarie a lungo termine e sul supporto delle decisioni aziendali strategiche.
Zymeworks Inc. (Nasdaq: ZYME) ha nombrado a Leone Patterson como Vicepresidente Ejecutivo y Directora de Negocios y Finanzas, con efecto a partir del 1 de septiembre de 2024. Con más de 20 años de experiencia en biotecnología en compañías públicas, Patterson aporta experiencia en la orientación de estrategias, finanzas, operaciones y gobernanza a través de varias fases de crecimiento. Será fundamental para apoyar el objetivo '5 by 5' de Zymeworks, que busca tener cinco nuevos conjugados de fármacos-anticuerpos o activadores de células T en estudios clínicos para 2026, y avanzar en los programas de I+D hacia estudios clínicos para 2027.
Los roles previos de Patterson incluyen el de Directora Financiera y de Negocios en Tenaya Therapeutics y posiciones de liderazgo en Adverum Biotechnologies. Actualmente, forma parte de las juntas directivas de Nkarta, Inc. y Oxford Biomedica. Con base en la nueva ubicación de Zymeworks en Redwood City, California, Patterson se centrará en desarrollar estrategias financieras a largo plazo y en apoyar decisiones empresariales estratégicas.
자이무웍스 주식회사(Zymeworks Inc., Nasdaq: ZYME)는 레오네 패터슨(Leone Patterson)을 부사장 겸 사업 및 재무 책임자로 임명하며, 2024년 9월 1일부터 효력을 발휘한다고 발표했습니다. 20년 이상의 공기업 생명공학 경험을 보유한 패터슨은 전략, 재무, 운영 및 기업 거버넌스를 다양한 성장 단계에서 안내하는 전문성을 제공합니다. 그녀는 자이무웍스의 '5 by 5' 목표, 즉 2026년까지 5개의 새로운 항체-약물 접합체 또는 T 세포 활성제가 임상 연구에 진입할 수 있도록 지원하고, 2027년까지 R&D 프로그램을 임상 연구로 진전시키는 데 중요한 역할을 할 것입니다.
패터슨의 이전 직책으로는 테나야 치료제(Tenaya Therapeutics)의 최고 재무 및 사업 책임자와 아드버럼 생명공학(Adverum Biotechnologies)의 리더십 포지션이 포함됩니다. 현재 그녀는 엔카르타(Nkarta, Inc.)와 옥스포드 바이오메디카(Oxford Biomedica)의 이사회에서 활동하고 있습니다. 캘리포니아 레드우드 시티에 있는 자이무웍스의 새로운 위치에 위치한 패터슨은 장기 재무 전략을 개발하고 전략적 비즈니스 결정을 지원하는 데 주력할 것입니다.
Zymeworks Inc. (Nasdaq: ZYME) a nommé Leone Patterson au poste de Vice-Président Exécutif et de Directeur des Affaires et Financier, avec effet au 1er septembre 2024. Forte de plus de 20 ans d'expérience dans le secteur biotechnologique des entreprises cotées en bourse, Patterson apporte son expertise pour guider les stratégies, les finances, les opérations et la gouvernance à travers différentes phases de croissance. Elle jouera un rôle crucial dans le soutien à l'objectif '5 by 5' de Zymeworks, qui consiste à avoir cinq nouveaux conjugats anticorps-médicaments ou activateurs de cellules T dans des études cliniques d'ici 2026, tout en faisant avancer les programmes de R&D vers des études cliniques d'ici 2027.
Avant ce poste, Patterson a été Directrice Financière et des Affaires chez Tenaya Therapeutics et a occupé des postes de direction chez Adverum Biotechnologies. Elle siège actuellement au conseil d'administration de Nkarta, Inc. et d'Oxford Biomedica. Basée dans la nouvelle localisation de Zymeworks à Redwood City, Californie, Patterson se concentrera sur le développement de stratégies financières à long terme et sur le soutien des décisions commerciales stratégiques.
Zymeworks Inc. (Nasdaq: ZYME) hat Leone Patterson zum Executive Vice President und Chief Business and Financial Officer ernannt, mit Wirkung zum 1. September 2024. Mit über 20 Jahren Erfahrung in der Biotech-Branche bei börsennotierten Unternehmen bringt Patterson Fachwissen in der strategischen Ausrichtung, Finanzmanagement, Betrieb und Governance durch verschiedene Wachstumsphasen mit. Sie wird eine entscheidende Rolle dabei spielen, Zymeworks' Ziel '5 by 5' zu unterstützen, welches vorsieht, bis 2026 fünf neuartige Antikörper-Arzneimittel-Konjugate oder T-Zell-Aktivatoren in klinischen Studien zu haben und Forschungs- und Entwicklungsprogramme bis 2027 in klinische Studien voranzubringen.
Pattersons vorherige Positionen umfassen Chief Financial and Business Officer bei Tenaya Therapeutics sowie Führungspositionen bei Adverum Biotechnologies. Derzeit ist sie im Vorstand von Nkarta, Inc. und Oxford Biomedica tätig. Mit Sitz in der neuen Location von Zymeworks in Redwood City, Kalifornien, wird Patterson sich darauf konzentrieren, langfristige Finanzstrategien zu entwickeln und strategische Unternehmensentscheidungen zu unterstützen.
- Appointment of experienced executive Leone Patterson as Chief Business and Financial Officer
- Patterson brings over 20 years of public company biotech experience
- Strengthens leadership team to support '5 by 5' goal and ADVANCE R&D programs
- Patterson's expertise in finance, operations, and governance through multiple growth phases
- None.
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024.
“After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks,” said Kenneth Galbraith, Chair and CEO of Zymeworks. “She brings more than 20 years of public company biotech experience with a proven track record of guiding strategy, finance, operations, and governance through multiple phases of growth, planning and executing successful financial strategies. Ms. Patterson has the financial leadership qualities to support Zymeworks as we continue to make progress in achieving our ‘5 by 5’ goal of having five novel antibody-drug conjugates or novel T cell engagers in clinical studies by 2026, and progress product candidates from our ADVANCE R&D programs into clinical studies by 2027 and beyond.”
“I am very pleased to be joining Zymeworks as the Company plans for many important milestones in the months and years ahead. I look forward to working collaboratively with the experienced leadership team in maximizing the value of the rapidly expanding pipeline and addressing many critical areas of unmet medical needs for patients with difficult-to-treat cancers and other serious diseases,” said Ms. Patterson.
Prior to joining Zymeworks, Ms. Patterson served as Chief Financial and Business Officer at Tenaya Therapeutics where she led corporate finance, investor relations, corporate communications, strategy and business development teams as well as other operational functions. She previously held leadership positions at Adverum Biotechnologies including Chief Financial Officer, President, Chief Executive Officer and Director. She also has held senior finance positions at Diadexus, Transcept, Exelixis, Novartis, and Chiron. Earlier in her career she worked in the audit practice of KPMG.
Ms. Patterson currently serves on the board of directors of Nkarta, Inc. and Oxford Biomedica, both publicly-held companies. She earned a B.S. in business administration and accounting from Chapman University and an executive MBA from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).
Ms. Patterson’s appointment builds on the Company’s continued focus on strengthening its leadership in the biopharmaceutical industry and expanding its pipeline of pharmaceutical candidates with the potential to make a significant difference in the lives of patients around the world with difficult-to-treat cancers and other diseases. She will be responsible for assisting with the development of Zymeworks’ long-term financial strategy, providing leadership surrounding financing and capital strategies and supporting strategic business decisions. She will be based in the new Zymeworks’ location in Redwood City, California.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Ms. Patterson’s anticipated appointment date; Ms. Patterson’s expected contributions to Zymeworks’ strategic goals; potential therapeutic effects and commercial potential of zanidatamab and Zymeworks’ other product candidates; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
When will Leone Patterson join Zymeworks (ZYME) as Chief Business and Financial Officer?
What is Zymeworks' (ZYME) '5 by 5' goal?
Where will Leone Patterson be based in her new role at Zymeworks (ZYME)?
What are Leone Patterson's previous work experiences before joining Zymeworks (ZYME)?
